Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement.
作者信息
van Ingen Jakko, Aksamit Timothy, Andrejak Claire, Böttger Erik C, Cambau Emmanuelle, Daley Charles L, Griffith David E, Guglielmetti Lorenzo, Holland Steven M, Huitt Gwen A, Koh Won-Jung, Lange Christoph, Leitman Philip, Marras Theodore K, Morimoto Kozo, Olivier Kenneth N, Santin Miguel, Stout Jason E, Thomson Rachel, Tortoli Enrico, Wallace Richard J, Winthrop Kevin L, Wagner Dirk
机构信息
Dept of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands
Division of Pulmonary and Critical Care Medicine, Dept of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
出版信息
Eur Respir J. 2018 Mar 22;51(3). doi: 10.1183/13993003.00170-2018. Print 2018 Mar.
Abstract
摘要
相似文献
1
Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement.
Eur Respir J. 2018 Mar 22;51(3). doi: 10.1183/13993003.00170-2018. Print 2018 Mar.
2
Poor adherence to management guidelines in nontuberculous mycobacterial pulmonary diseases.
Eur Respir J. 2017 Feb 15;49(2). doi: 10.1183/13993003.01855-2016. Print 2017 Feb.
3
British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD).
Thorax. 2017 Nov;72(Suppl 2):ii1-ii64. doi: 10.1136/thoraxjnl-2017-210927.
4
Antibiotic treatment for nontuberculous mycobacterial lung disease.
Expert Rev Respir Med. 2016;10(5):557-68. doi: 10.1586/17476348.2016.1165611. Epub 2016 Mar 30.
5
Medical Management of Pulmonary Nontuberculous Mycobacterial Disease.
Thorac Surg Clin. 2019 Feb;29(1):65-76. doi: 10.1016/j.thorsurg.2018.09.001.
6
Adjuvant surgical treatment of nontuberculous mycobacterial lung disease.
Ann Thorac Surg. 2013 Jul;96(1):287-91. doi: 10.1016/j.athoracsur.2013.03.008. Epub 2013 Apr 22.
7
Recent advances in nontuberculous mycobacterial lung infections.
F1000Res. 2019 Oct 1;8. doi: 10.12688/f1000research.20096.1. eCollection 2019.
8
Paediatric lung transplant outcomes vary with Mycobacterium abscessus complex species.
Eur Respir J. 2013 May;41(5):1230-2. doi: 10.1183/09031936.00143512.
9
Population-based Incidence of Pulmonary Nontuberculous Mycobacterial Disease in Oregon 2007 to 2012.
Ann Am Thorac Soc. 2015 May;12(5):642-7. doi: 10.1513/AnnalsATS.201412-559OC.
10
Early onset of nontuberculous mycobacterial pulmonary disease contributes to the lethal outcome in lung transplant recipients: report of two cases and review of the literature.
Transpl Infect Dis. 2016 Feb;18(1):112-9. doi: 10.1111/tid.12481. Epub 2016 Jan 30.
引用本文的文献
1
Risk factors, molecular analysis and treatment outcomes of amikacin-resistant complex pulmonary disease.
ERJ Open Res. 2025 Aug 11;11(4). doi: 10.1183/23120541.01084-2024. eCollection 2025 Jul.
2
IFNGR1, IRF8 genetic polymorphisms modulate the susceptibility of non-tuberculous mycobacteria pulmonary disease and influence the patients' treatment outcomes and immune status.
Inflamm Res. 2025 Jul 22;74(1):106. doi: 10.1007/s00011-025-02071-y.
3
Non-tuberculous mycobacterial disease in a high TB/HIV burden setting.
IJTLD Open. 2025 Jul 9;2(7):437-439. doi: 10.5588/ijtldopen.25.0205. eCollection 2025 Jul.
4
Treatment Outcomes of Complex Pulmonary Disease with a 2-drug Daily Regimen Using Macrolide and Ethambutol.
Open Forum Infect Dis. 2025 May 13;12(6):ofaf292. doi: 10.1093/ofid/ofaf292. eCollection 2025 Jun.
5
Recombinant interleukin-7 treatment of refractory complex lung disease (IMPULSE-7): a pilot phase II, single-center, randomized, clinical trial.
Ther Adv Infect Dis. 2025 May 10;12:20499361251339300. doi: 10.1177/20499361251339300. eCollection 2025 Jan-Dec.
6
Malignant Pleural Mesothelioma: From Pathophysiology to Innovative Actionable Targets.
Cancers (Basel). 2025 Mar 30;17(7):1160. doi: 10.3390/cancers17071160.
7
Effect of Individual Agents on Time to Culture Conversion in Complex Pulmonary Disease.
Open Forum Infect Dis. 2025 Mar 7;12(3):ofaf138. doi: 10.1093/ofid/ofaf138. eCollection 2025 Mar.
8
Differences in sputum microbiota based on cure status of patients with nontuberculous mycobacterial pulmonary disease.
Korean J Intern Med. 2025 May;40(3):449-457. doi: 10.3904/kjim.2024.209. Epub 2025 Mar 25.
9
Effects of Amikacin Liposome Inhalation Suspension and Amikacin Resistance Development in Patients With Refractory Complex Pulmonary Disease.
Open Forum Infect Dis. 2025 Mar 1;12(3):ofaf118. doi: 10.1093/ofid/ofaf118. eCollection 2025 Mar.
10
A Rare Pathogenic Masquerader of Pulmonary Disease: A Case Report.
Cureus. 2025 Feb 10;17(2):e78822. doi: 10.7759/cureus.78822. eCollection 2025 Feb.
本文引用的文献
1
British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD).
Thorax. 2017 Nov;72(Suppl 2):ii1-ii64. doi: 10.1136/thoraxjnl-2017-210927.
2
Treatment and outcome of non-tuberculous mycobacterial pulmonary disease in a predominantly fibro-cavitary disease cohort.
Respir Med. 2017 Oct;131:220-224. doi: 10.1016/j.rmed.2017.08.031. Epub 2017 Sep 1.
3
Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease.
Am J Respir Crit Care Med. 2017 Mar 15;195(6):814-823. doi: 10.1164/rccm.201604-0700OC.
4
Treatment Outcomes in Multidrug-Resistant Tuberculosis.
N Engl J Med. 2016 Sep 15;375(11):1103-5. doi: 10.1056/NEJMc1603274.
5
Diagnostic Molecular Mycobacteriology in Regions With Low Tuberculosis Endemicity: Combining Real-time PCR Assays for Detection of Multiple Mycobacterial Pathogens With Line Probe Assays for Identification of Resistance Mutations.
EBioMedicine. 2016 Jul;9:228-237. doi: 10.1016/j.ebiom.2016.06.016. Epub 2016 Jun 14.
6
Update on pulmonary disease due to non-tuberculous mycobacteria.
Int J Infect Dis. 2016 Apr;45:123-34. doi: 10.1016/j.ijid.2016.03.006. Epub 2016 Mar 11.
7
Methodological and Clinical Aspects of the Molecular Epidemiology of Mycobacterium tuberculosis and Other Mycobacteria.
Clin Microbiol Rev. 2016 Apr;29(2):239-90. doi: 10.1128/CMR.00055-15.
8
US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis.
Thorax. 2016 Jan;71 Suppl 1(Suppl 1):i1-22. doi: 10.1136/thoraxjnl-2015-207360.
9
Improvement in Quality of Life after Therapy for Mycobacterium abscessus Group Lung Infection. A Prospective Cohort Study.
Ann Am Thorac Soc. 2016 Jan;13(1):40-8. doi: 10.1513/AnnalsATS.201508-529OC.
10
Semiquantitative Culture Analysis during Therapy for Mycobacterium avium Complex Lung Disease.
Am J Respir Crit Care Med. 2015 Sep 15;192(6):754-60. doi: 10.1164/rccm.201503-0444OC.
Zotero 插件